The AstraZeneca share price is at all-time highs. Should investors be wary?

Shares of AstraZeneca plc (LON: AZN) look too expensive to me right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Amid a choppy market environment, shares of AstraZeneca (LSE: AZN) are performing extremely well. But is this a reason to buy them at their current price? Let’s examine the reasons behind the stock’s performance, as well as whether the current valuation represents an attractive investment opportunity.

Recent successes

Although the last year was an up and down period for AstraZeneca shareholders, patient investors were rewarded with a strong trading update in July. Priced at 7,327p a share, the stock is currently trading at all-time highs, and it’s easy to see why. Product sales were up 17% in the first half of 2019, and total revenue increased by 14%. 

Both revenue and earnings per share beat analysts’ expectations — the former by $251m (£207m) and the latter by $0.13/share (£0.11/share). This outperformance has driven the stock higher by over 15% since the release of the earnings report. 

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Drug sales are on the rise

Over the last few years, AstraZeneca has been increasing its investment in its oncology division, and these trading results are evidence of that. Revenue from the oncology segment as a whole grew by 58% in the first half of 2019. These increases were led by lung cancer drug Tagrisso (£1.16 bn) and ovarian cancer treatment Lynparza (£429m), as well as Imfinzi (£547m), prescribed for bladder and urinary tract cancers. 

A few months ago I wrote that CEO Pascal Soriot deserves a lot of credit for AstraZeneca’s much-improved results. It was his vision to move the company to focus on oncology treatment, and this strategy seems to be bearing fruit. Nevertheless, I believe that from an investment standpoint, the business is just too expensive to buy.

Too rich for my blood

Shares of AstraZeneca currently trade at a forward price-to-earnings ratio of 24, well above the PE ratio for the FTSE 100 as a whole, which stands at 15.6. Moreover, it yields a dividend of 3.18%, which is also below the FTSE 100 average (4.74%). And as my colleague Roland Head points out, the company’s net debt has risen significantly over the last four years — from £6.43bn to £13.44bn. He believes that management’s desire to maintain the dividend at current levels has forced it to rely on debt to fund investment, and I agree.

Companies that have above-average valuations tend to underperform, statistically speaking. This is particularly true in times of higher volatility, as has been the case in recent months. When everything is falling, those who bought highest will suffer the most pain. 

There is also the nagging uncertainty surrounding how Brexit will affect the entire pharmaceutical industry. If a no-deal scenario does materialise, that could seriously impact the ability of AstraZeneca (and other companies in the sector) to export drugs to the European Union. I believe that the market is not accurately pricing in this possibility, and for these reasons I’ll be staying away from this stock. 

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

Here’s how long it’s taken £1k of Nvidia stock to turn into £10k today!

Our writer explains how money invested in Nvidia stock less than three years ago has grown in value over tenfold…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
US Stock

3 red flags I’m seeing right now for the S&P 500

Jon Smith points out some concerns he has with the S&P 500 at current levels and picks one stock he's…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

UK dividend shares are outperforming US tech stocks!

UK dividend shares aren’t just for passive income investors. Over the last 12 months, they’ve been outperforming their US tech…

Read more »

DIVIDEND YIELD text written on a notebook with chart
US Stock

Here’s how much passive income an investor could make with £2k in Meta stock

Jon Smith looks at Meta stock from a different angle to normal, considering it as an option for an investor's…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

1 of my top UK shares is up 15% in a day! Is it still a buy for me?

Celebrus shares are soaring after strong full-year results. At a P/E ratio below 13, is it one of the best…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

£10,000 invested in Jet2 shares 2 years ago is now worth…

Jet2 shares have surged in recent months and finally appear to be pushing towards fair value. Dr James Fox shares…

Read more »

piggy bank, searching with binoculars
Investing Articles

This FTSE 100 blue-chip could rise 26% in 12 months, according to brokers

While this FTSE 100 dividend stock has put investors through the wringer in recent years, some analysts see brighter skies…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

A 3-step passive income strategy to target major wealth

Want to invest in the stock market to build up a passive income stream? There's no fiendlishly complex multi-step mystique…

Read more »